1. <menuitem id="nbjb9"><p id="nbjb9"></p></menuitem>
      <nav id="nbjb9"><strike id="nbjb9"><bdo id="nbjb9"></bdo></strike></nav>
      1. <s id="nbjb9"><b id="nbjb9"><noscript id="nbjb9"></noscript></b></s>
        

      2. <rt id="nbjb9"><cite id="nbjb9"><samp id="nbjb9"></samp></cite></rt>

        <rt id="nbjb9"><option id="nbjb9"></option></rt>

        CN  /  EN

        imgboxbg

        NEWS

        最新消息

        数据抓取行为引发的商标侵权

        • 分类:最新消息
        • 作者:华讯知识产权
        • 来源:
        • 发布时间:2021-12-23 15:28
        • 访问量:

        【概要描述】

        数据抓取行为引发的商标侵权

        【概要描述】

        • 分类:最新消息
        • 作者:华讯知识产权
        • 来源:
        • 发布时间:2021-12-23 15:28
        • 访问量:
        详情

        关于商标侵权,简单来说,不经商标权人同意,使用他人商标就可能侵权,不管用作商标、商品名称、字号、域名、商品装潢等,只要消费者能够从这个标志的使用来识别商品来源,误以为与权利商标是一家的或者相关,都可能涉及商标侵权。

        例如上海市浦东新区人民法院近日受理的“小红书”与“识季”的商标纠纷案, 据了解,“识季”App未经原告许可就在商品图片中使用“小红书”标识并将“小红书街拍”设置为商品标签及搜索关键词,还通过不正当手段大量抓取“小红书”平台的图片,并将其用于自身商品的宣传。该案情涉及了电商平台间数据抓取行为引发的新型不正当竞争纠纷,法院拟于2022年初对此案进行公开开庭审理

        一般来说,是否构成不正当竞争行为应从以下四方面界定:

        • 一是不正当竞争行为的主体是经营者。
        • 二是不正当竞争行为以市场竞争为目的。
        • 三是不正当竞争行为违反诚实信用原则和公认的商业道德。
        • 四是不正当竞争行为损害多方利益。

        如果原告能从以上几个方面证明损害事实存在,那么可要求对方停止侵权行为,并及时减少相应的损害。但随着互联网科技的迅猛发展,网络大数据产品市场价值的法律属性及权利归属矛盾也日益凸显,比起仿冒商标或制假售假等明显的商标侵权行为,类似“小红书”和“识季” 这种商标纠纷则愈发常见

        数据抓取技术涉及到的网络大数据产品,是网络运营者经过大量的智力劳动,深度开发与系统整合成的独立于网络用户信息、原始网络数据之外的衍生数据,实质性具备了商品的交换价值。对于网络运营者而言,网络大数据产品已成为其拥有的一项重要的财产权益。而当前,是否赋予网络运营者享有大数据产品财产所有权,业内也存在争议,首要问题就是如何解释“其他妨碍、破坏其他经营者合法提供的网络产品或者服务正常运行的行为”。

        实践中,当事人为确保自己有充分的请求权基础,可通过合同的方式将权利边界予以明确。在对抓取行为缺少直接证据的情况下,权利方可尝试从结果层面予以补充和加强。另外,企业在商标注册成功以后,还应对其名下的商标做好商标监测工作,发现问题可迅速做出应对措施,避免不必要的损失,防止企业品牌信誉受到影响,也可和专业的知识产权服务机构达成长期合作,助力商标品牌的培育和企业知识产权全方位保护。

        Ruige

        Ruige Pharmaceutical's New Generation of CDK2/4/6 Small-molecule Inhibitor Receives FDA Approval for Clinical Research

        Established in 2018, Ruige Pharmaceutical?is committed to the fields of tumors, autoimmunity and metabolism, and develops "first-in-class" and "best-in-class" innovative drugs with independent intellectual property rights. Recently, Ruige Pharmaceutical?announced that its new generation of CDK2/4/6 small- molecule inhibitor RGT-419B has been received FDA approval for clinical research. RGT-419B is a new-generation tumor-targeted inhibitor with an optimized kinase activity spectrum. It is expected to improve the safety of currently approved CDK4/6 inhibitors and overcome resistance to these inhibitors. These inhibitors are used in combination with endocrine therapy to treat patients with premenopausal/postmenopausal hormone receptor positive (HR+) and human epidermal growth factor receptor 2 negative (HER2-) advanced or metastatic breast cancer. In cell model experiments, RGT-419B showed single-drug activity, which has a greater inhibitory effect on the growth of estrogen receptor positive (ER+) tumor cells. In ER+ breast cancer cells resistant to currently approved CDK4/6 inhibitors, RGT-419B showed complete inhibition of cancer cell proliferation. In these experiments, when RGT-419B is used in combination with a selective estrogen receptor degrader or PI3K signaling pathway inhibitor, its inhibitory effect on tumor cells is further enhanced. As a single agent and used in combination with other approved therapies, RGT-419B will initially be developed for the treatment of human epidermal growth factor receptor 2 negative (HER2-), ER+ breast cancer patients who have primary or acquired resistance to CDK4/6 inhibitors. With the widespread adoption of CDK4/6 inhibitors in clinical practice, patients with refractory and relapsed patients are becoming larger and clinically significant unmet medical needs. The clinical development project of RGT-419B will solve this resistance to CDK4/6 and other hormone receptor modulating therapies, and provide new opportunities for improving the survival and quality of life of patients with advanced breast cancer. RGT-419B is the first of many innovative oncology drugs being developed by Ruige Pharmaceutical. Founder and CEO Dr. Qiu Xiayang said: "This milestone marks the successful entry of Ruige Pharmaceutical into the field of tumor treatment. We have found the best choice for multiple CDKs through our self-developed AI-assisted new drug development CARD platform. Successfully promoted innovative drugs to enter the clinical development stage in the United States. At the same time, we are very excited that this opportunity can bring new and differentiated treatment options to many breast cancer patients around the world.
        2021-12-30
        台湾华讯入驻台湾国际半导体大会

        台湾华讯入驻台湾国际半导体大会

        此次大会全称为台湾国际半导体展(SEMICON Taiwan 2021)由国际半导体产业协会(SEMI)主办。
        2021-12-28
        华讯参展2021云上南京软博会

        华讯参展2021云上南京软博会

        华讯一直行走在软件信息的专利顾问服务前沿,紧跟软件信息产业发展的脚步,致力于为企业提供最专业的知识产权服务,为中国软件信息产业的发展出一份力。
        2021-12-27
        原告被告都是国外企业

        原告被告都是国外企业 他们竟纷纷选择到中国提起诉讼?

        这是一个有趣的趋势:由于种种原因,国外企业纷纷选择在中国提起专利诉讼,起诉非中国企业。
        2021-12-24
        上一页
        1
        2
        ...
        145
        这是描述信息

        江苏省南京市江北新区江淼路88号腾飞大厦B座20层2001

        版权所有◎南京华讯知识产权顾问有限公司

        备案号:苏ICP备xxxxxx号-1    网站建设:中企动力 南京

        亚洲AV无码一区二区乱子伦,久久精品中文字幕一区,色费女人18毛片A级毛片视频,欧美+日本+国产+A∨观看